Compare iShares MSCI Indonesia ETF (EIDO) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Eli Lilly And Co — how do they compare? iShares MSCI Indonesia ETF trades at $11.89 (market cap $409.22M), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 2541.4× iShares MSCI Indonesia ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Eli Lilly And Co for 93 Days on average.
| EIDO | LLY | |
|---|---|---|
Market Cap | $409.22M | $1.04T |
Volume | 879,527 | 3,064,878 |
52-Week High | $19.22 | $1.28K |
52-Week Low | $10.80 | $799.57 |
Typical Hold Time | 76 Days | 93 Days |
Sector | — | Health |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.67, down 1.6% with bearish technical signals from moving averages and mixed oscillators. The ETF faces weak price action despite a low P/E ratio of 8.7x, with heavy financial sector exposure (44%) limiting growth potential. Recent news highlights foreign capital outflows from Asian markets and Indonesia's failure to benefit from commodity gains, contributing to negative sentiment.
The outlook remains cautious with technical downtrends and structural growth constraints. Investment opportunity lies in valuation discount, but risks include sector concentration and regional capital rotation. Upside depends on improved foreign inflows and commodity-driven economic momentum.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
